| Literature DB >> 34749674 |
Atsedewoyn Firesbhat1, Abiye Tigabu2, Birhanemeskel Tegene3, Baye Gelaw4.
Abstract
BACKGROUND: The hospital environment serves as a source of nosocomial infections, which pose a major therapeutic challenge. Although many bacteria species are common in hospital environments, their distribution, frequency, and antimicrobial susceptibility pattern from high-touch surfaces, leftover drugs, and antiseptics in different wards remain largely unknown. Hence, the aim of this study was to assess the magnitude and frequency of bacterial contaminants and their antimicrobial susceptibility patterns.Entities:
Keywords: Antiseptics; Bacterial profile; High touch surfaces; Leftover drugs
Mesh:
Substances:
Year: 2021 PMID: 34749674 PMCID: PMC8573887 DOI: 10.1186/s12866-021-02378-w
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Fig. 1Proportion of bacterial isolates from 80% ethanol, leftover drugs and high touch surfaces from December 2020 to March 2021
Frequency of Gram-positive and Gram-negative bacteria from December 2020 to March 2021
| Types of species | Frequency (N) | Percent (%) | |
|---|---|---|---|
| CoNS | 44 | 38.6% | |
| 15 | 13.2% | ||
| 9 | 7.9% | ||
| Viridans streptococci | 3 | 2.63% | |
| 2 | 1.75% | ||
| 1 | 0.88% | ||
| 13 | 11.4% | ||
| 10 | 8.8% | ||
| 9 | 7.9% | ||
| 4 | 3.51% | ||
| 2 | 1.75% | ||
| 1 | 0.88% | ||
| 1 | 0.88% | ||
CoNS coagulase negative Staphylococci
The proportion of bacteria isolated from different wards at UoGCSH from December 2020 to March 2021
| Bacterial isolates | Type of ward | |||||
|---|---|---|---|---|---|---|
| Surgical | Post-natal | Orthopedic | Trauma | NICU | Total | |
| CoNS | 12 (42.9) | 4 (16.7) | 13 (56.5) | 9 (42.9) | 6 (33.3) | 44 (38.6) |
| 3 (10.7) | 5 (20.8) | 4 (17.4) | 2 (9.5) | 1 (5.6) | 15 (13.2) | |
| 1 (3.6) | 4 (16.7) | – | 2 (9.5) | 2 (11.1) | 9 (7.8) | |
| Viridans streptococci | – | 1 (4.2) | 1 (4.3) | 1 (4.8) | – | 3 (2.6) |
| – | 1 (4.2) | – | – | 1 (5.6) | 2 (1.8) | |
| – | 1 (4.2) | – | – | – | 1 (0.9) | |
| 11 (39.3) | 2 (8.3) | – | – | – | 13 (11.4) | |
| – | 3 (12.5) | – | 2 (9.5) | 5 (27.8) | 10 (8.8) | |
| 1 (3.6) | 1 (4.2) | 2 (8.7) | 3 (14.3) | 2 (11.1) | 9 (7.8) | |
| – | 1 (4.2) | 1 (4.3) | 1 (4.8) | 1 (5.6) | 4 (3.5) | |
| – | – | 2 (8.7) | – | – | 2 (1.8) | |
| – | – | – | 1 (4.8) | – | 1 (0.9) | |
| – | 1 (4.2) | – | – | – | 1 (0.9) | |
CoNS coagulase negative Staphylococci, NICU Neonatal Intensive Care Unit
The proportion of bacterial isolates at UoGCSH from December 2020 to March 2021
| Isolated bacteria, n (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sampling points | CoNS | Total n (%) | ||||||||||
| Bed sheet | 19 (43.2) | 6 (40) | 2 (22.2) | 0 (0) | 0 (0) | 5 (38.5) | 1 (9.1) | 2 (22.2) | 0 (0) | 0 (0) | 1 (100) | 36 (31.6) |
| Bed side table | 14 (31.8) | 8 (53.3) | 5 (55.6) | 1(20) | 0 (0) | 5 (38.5) | 1 (9.1) | 0 | 3 (75) | 0 (0) | 0 (0) | 37 (32.5) |
| Sink | 3 (6.8) | 0 (0) | 0 (0) | 2 (40) | 0 (0) | 3 (23.1) | 9 (81.8) | 5 (55.6) | 1 (25) | 2 (100) | 0 (0) | 25 (21.9) |
| Door handles | 5 (11.4) | 0 (0) | 0 (0) | 1 (20) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (5.3) |
| Blood culture table | 1 (2.3) | 1 (6.7) | 2 (22.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (3.5) |
| 80% ethanol | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 2 (22.2) | 0 (0) | 0 (0) | 0 (0) | 4 (3.5) |
| Leftover drugs | 1 (2.3) | 0 (0) | 0 (0) | 1 (20) | 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1.8) |
CoNS coagulase negative Staphylococci
AST of Gram-positive bacteria at UoGCSH from December 2020 to March 2021
| Bacterial isolates (n) | Antimicrobial agents | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pattern | ERY | CD | GEN | P | CXT | TE | DOX | CIP | COT | CFP | VAN | AMP | |
| 17 (38.6) | 28 (63.6) | 29 (65.9) | 14 (31.8) | 22 (50) | 22 (50) | 28 (63.6) | 22 (50) | 10 (22.7) | ND | ND | ND | ||
| 27 (61.4) | 16 (36.4) | 15 (34.1) | 30 (68.2) | 22 (50) | 22 (50) | 16 (36.4) | 22 (50) | 34 (77.3) | ND | ND | ND | ||
| 7 (46.7) | 7 (46.7) | 8 (53.3) | 4 (26.7) | 2 (13.3) | 6 (40) | 6 (40) | 9 (60) | 8 (53.3) | ND | ND | ND | ||
| 8 (53.3) | 8 (53.3) | 7 (46.7) | 11(73.3) | 13 (86.7) | 9 (60) | 9 (60) | 6 (40) | 7 (46.7) | ND | ND | ND | ||
| ND | ND | 6 (66.7) | 4 (44.4) | ND | ND | ND | ND | ND | ND | 6 (66.7) | 7 (77.8) | ||
| ND | ND | 3 (33.3) | 5 (55.6) | ND | ND | ND | ND | ND | ND | 3 (33.3) | 2 (22.2) | ||
| 1 (33.3) | 1 (33.3) | ND | ND | ND | 1 (33.3) | ND | ND | ND | 1 (33.3) | 1 (33.3) | ND | ||
| 2 (66.7) | 2 (66.7) | ND | ND | ND | 2 (66.7) | ND | ND | ND | 2 (66.7) | 2 (66.7) | ND | ||
| 2 (100) | 0 | ND | 0 | ND | 0 | ND | ND | ND | 0 | 0 | ND | ||
| 0 | 2 (100) | ND | 2 (100) | ND | 2 (100) | ND | ND | ND | 2 (100) | 2 (100) | ND | ||
| Total (73) | 27 (42.2) | 36 (56.3) | 43 (63.2) | 22 (32.4) | 24 (40.7) | 29 (46.8) | 34 (57.6) | 31 (52.5) | 18 (30.5) | 1 (20) | ND | 7 (77.8) | |
| 37 (57.8) | 28 (43.7) | 25 (36.8) | 46 (67.6) | 35 (59.3) | 33 (53.2) | 25 (42.4) | 28 (47.5) | 41 (67.8) | 4 (80) | ND | 2 (22.2) | ||
AST antimicrobial susceptibility test, CoNS coagulase negative Staphylococci, ERY erythromycin, CD clindamycin, GEN gentamicin, PEN penicillin, CXT cefoxitin, TE tetracycline, DOX doxycycline, CIP ciprofloxacin, COT cotrimoxazole, CFP cefepime, VAN vancomycin, AMP ampicillin, ND susceptibility test not done, S susceptible, NS non-susceptible
AST of Gram-negative bacteria at UoGCSH from December 2020 to March 2021
| Antimicrobial agents | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacterial isolates (n) | Sensitivity pattern | TE | CIP | AMC | AN | CXM | GEN | CFP | COT | IPM | CAZ | PRL | MPN |
| ND | 1 (7.7) | ND | 11 (84.6) | ND | 13 (100) | 0 | ND | 9 (69.2) | 0 | 1 (7.7) | ND | ||
| ND | 12 (92.3) | ND | 2 (15.4) | ND | 0 | 13 (100) | ND | 4 (23.1) | 13 (100) | 12 (92.3) | ND | ||
| ND | 8 (88.9) | ND | 8 (88.9) | ND | 5 (55.6) | 3 (33.3) | 7 (77.8) | 7 (77.8) | 4 (44.4) | ND | ND | ||
| ND | 1 (11.1) | ND | 1 (11.1) | ND | 4 (44.4) | 6 (66.7) | 2 (22.2) | 2 (22.2) | 5 (55.6) | ND | ND | ||
| 2 (20) | 5 (50) | 2 (20) | 9 (90) | 5 (50) | 7 (70) | 7 (70) | 7 (70) | 7 (70) | 6 (60) | ND | ND | ||
| 8 (80) | 5 (50) | 8 (50) | 1 (10) | 5 (50) | 3 (30) | 3 (30) | 3 (30) | 3 (30) | 4 (40) | ND | ND | ||
| 0 | 3 (75) | 1 (25) | 4 (100) | 2 (50) | 2 (50) | 1 (25) | 1 (25) | 4 (100) | 2 (50) | ND | ND | ||
| 4 (100) | 1 (25) | 3 (75) | 0 | 2 (50) | 2 (50) | 3 (50) | 3 (75) | 0 | 2 (50) | ND | ND | ||
| 0 | 0 | 1 (50) | 2 (100) | 0 | 2 (100) | 1 (50) | 0 | 2 (100) | 0 | ND | ND | ||
| 2 (100) | 2 (100) | 1 (50) | 0 | 2 (100) | 0 | 1 (50) | 2 (100) | 0 | 2 (100) | ND | ND | ||
| 1 (100) | 1 (100) | 0 | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | ND | ND | ||
| 0 | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ND | ND | ||
| ND | ND | ND | ND | ND | ND | ND | 0 | ND | 0 | ND | 1 (100) | ||
| ND | ND | ND | ND | ND | ND | ND | 1 (100) | ND | 1 (100) | ND | 0 | ||
| Total (40) | 3 (17.6) | 18 (46.2) | 4 (23.5) | 35 (89.7) | 8 (47) | 31 (79.5) | 13 (33.3) | 16 (94.1) | 30 (76.9) | 13 (32.5) | 1 (7.7) | 1 (100) | |
| 14 (82.4) | 21 (53.8) | 13 (76.5) | 4 (10.3) | 9 (53) | 8 (20.5) | 26 (66.7) | 11 (5.9) | 9 (23.1) | 27 (67.5) | 12 (92.3) | 0 | ||
AST antimicrobial susceptibility test, TE tetracycline, CIP ciprofloxacin, AMC amoxicillin clavulanic acid, AN amikacin, CXM cefuroxime, GEN gentamicin, CFP cefepime, COT cotrimoxazole, IPM imipenem, CAZ ceftazidime, PRL piperacillin, MPN meropenem, ND susceptibility test not done, S susceptible, NS non-susceptible
MDR pattern of bacterial isolates at UoGCSH from December 2020 to March 2021
| Bacterial isolates | Number of MDR isolates (%) | Antimicrobials resisted by most isolates |
|---|---|---|
| CoNS | 26/44 (59.1) | ERY, PEN, COT |
| 10/15 (66.7) | CD, PEN, CXT, TE, DOX | |
| 2/3 (66.7) | ERY, CD, TE, CFP, VAN | |
| 2/2 (100) | PEN, CD, CFP, TE, VAN | |
| 4/13 (30.8) | CIP, CAZ, CFP, PRL | |
| 3/10 (30) | TE, CIP, AMC, CXM | |
| 2/4 (50) | AMC, TE, COT | |
| 2/2 (100) | CAZ, CXM, COT, CIP, TE |
MDR multi-drug resistant, CoNS coagulase negative Staphylococci, ERY erythromycin, PEN penicillin, COT cotrimoxazole, CD clindamycin, CXT cefoxitin, TE tetracycline, DOX doxycycline, CFP cefepime, VAN vancomycin, CIP ciprofloxacin, CIP ciprofloxacin, CAZ ceftazidime, PRL piperacillin, AMC amoxicillin clavulanic acid, CXM cefuroxime